Dr Jeffrey Hausfeld Archives · BioBuzz

Loading …

BioFactura Raising Series B Investment to Advance Lead Biosimilar into Phase One

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-100x100.png 100w, https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-150x150.png 150w" data-src="https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-300x300.png" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-300x300.png" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-100x100.png 100w, https://biobuzz.io/wp-content/uploads/2018/05/BioFactura-featured-150x150.png 150w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : May 29, 2018May 29, 2018 Published by : Chris Frew

BioFactura Raising Series B Investment to Advance Lead Biosimilar into Phase One Dr. Jeffrey Hausfeld, BioFactura’s Chairman of the Board and Chief Medical Officer has been tasked with raising a Series [….]